Literature DB >> 11246681

Primary Sjögren's syndrome--treatment of fetal incomplete atrioventricular block with dexamethasone.

E Theander1, A Brucato, S Gudmundsson, S Salomonsson, M Wahren-Herlenius, R Manthorpe.   

Abstract

Pregnancies in women with autoantibodies against Ro/SSA and/or La/SSB may be associated with permanent and treatment resistant fetal atrioventricular (AV) block. We describe a patient with primary S ogren's syndrome and anti-Ro (60 kDa and 52 kDa) and anti-La autoantibodies, in whom fetal bradycardia with second-degree AV block was detected at 19 + 0 weeks of gestation. Maternal treatment with dexamethasone (4 mg/day po) was started 2 days later. The baby's heart rate improved gradually, returning to normal after about 6 weeks of treatment. Our case illustrates the importance of close monitoring of the fetal heart rate in risk-pregnancies from about week 16 of gestation and initiation of dexamethasone treatment without delay when a block is detected.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11246681

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  7 in total

Review 1.  Neonatal lupus.

Authors:  Antonio Brucato; Rolando Cimaz; Marco Stramba-Badiale
Journal:  Clin Rev Allergy Immunol       Date:  2002-12       Impact factor: 8.667

2.  Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero.

Authors:  A Brucato; M G Astori; R Cimaz; P Villa; M Li Destri; L Chimini; R Vaccari; M Muscarà; M Motta; A Tincani; F Neri; S Martinelli
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

Review 3.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

4.  Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block.

Authors:  L Strandberg; O Winqvist; S-E Sonesson; S Mohseni; S Salomonsson; K Bremme; J P Buyon; H Julkunen; M Wahren-Herlenius
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

5.  Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block.

Authors:  Stina Salomonsson; Sven-Erik Sonesson; Lars Ottosson; Saad Muhallab; Tomas Olsson; Maria Sunnerhagen; Vijay K Kuchroo; Peter Thorén; Eric Herlenius; Marie Wahren-Herlenius
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

6.  Difference in clinical presentation between women and men in incident primary Sjögren's syndrome.

Authors:  Jorge I Ramírez Sepúlveda; Marika Kvarnström; Susanna Brauner; Chiara Baldini; Marie Wahren-Herlenius
Journal:  Biol Sex Differ       Date:  2017-05-12       Impact factor: 5.027

7.  First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry).

Authors:  Micaela Fredi; Laura Andreoli; Beatrice Bacco; Tiziana Bertero; Alessandra Bortoluzzi; Silvia Breda; Veronica Cappa; Fulvia Ceccarelli; Rolando Cimaz; Salvatore De Vita; Emma Di Poi; Elena Elefante; Franco Franceschini; Maria Gerosa; Marcello Govoni; Ariela Hoxha; Andrea Lojacono; Luca Marozio; Alessandro Mathieu; Pier Luigi Meroni; Antonina Minniti; Marta Mosca; Marina Muscarà; Melissa Padovan; Matteo Piga; Roberta Priori; Véronique Ramoni; Amelia Ruffatti; Chiara Tani; Marta Tonello; Laura Trespidi; Sonia Zatti; Stefano Calza; Angela Tincani; Antonio Brucato
Journal:  Front Cardiovasc Med       Date:  2019-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.